Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 17
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/5/2007
 
First Published:
5/1/1999
1.
Phase III Randomized Study of Ciprofloxacin vs Cephalexin in Patients with Stage Ta Transitional Cell Carcinoma of the Bladder Treated with Transurethral Tumor Resection
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
SWOG-S9809
CLB-S9809, NCT00003824, S9809
2.
Phase III Empirical Antimicrobial Therapy vs Early Open Lung Biopsy/Specific Therapy for Diffuse Interstitial Pneumonitis in Immunocompromised Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Completed
no age specified
NCI-82-C-111
3.
Phase III Management and Prophylaxis of Fever and Infection with Antimicrobial Treatment in Cancer Patients (Study III)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
no age specified
NCI-81-C-189
NCI-POB-8103
Last Modified:
11/22/2006
4.
Phase III Comparison of ARA-C/DNM/TG vs ARA-C/VCR/DM for Remission Induction plus Intensive Multi-Drug Maintenance for Previously Untreated Pediatric ANLL
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
21 and under
NCI
POG-8101
POG-ANLL-2, POG-8101
Last Modified:
6/14/2007
5.
NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Comparison of CHOP (CTX/ADR/VCR/PRED) vs m-BACOD (CTX/ADR/VCR/BLEO/DM/MTX/CF) vs ProMACE-CytaBOM (CTX/ADR/VP-16/PRED/ARA-C/BLEO/VCR/MTX/CF) vs MACOP-B (MTX/CF/ADR/VCR/BLEO/PRED) in Patients with Intermediate- or High-Grade non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
NCI
SWOG-8516
EST-3487, INT-0067
6.
Phase III Randomized Study of Initial Empiric Antimicrobial Therapy with TMP-SMX/Erythromycin and Other Antibiotics as Indicated vs Pretreatment Bronchoalveolar Lavage and Pathogen-Specific Therapy in Immunocompromised Patients with Diffuse Interstitial Pneumonitis (Summary last modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Completed
no age specified
NCI
NCI-86-C-26
NCI-T86-0081N, T86-0081
Last Modified:
4/1/1997
7.
Phase III Pilot Chemotherapy with Short-Course ProMACE-CytaBOM (CTX/ADR/VP-16/ARA-C/BLEO/VCR/MTX/PRED) for the Treatment of Patients with Stages II-IV Diffuse Aggressive Lymphomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
over 18
NCI
CRB-8807E
NCI-87-C-180C, NCI-T87-0307N, T87-0307
Last Modified:
4/23/2007
8.
Phase III Randomized Study of Continuous-Infusion vs Bolus High-Dose ARA-C During Induction and of Intensification with VP-16/IFF vs No Intensification in Children and Adolescents with Stage III/IV Diffuse Undifferentiated non-Hodgkin's Lymphoma or B-Cell ALL
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
21 and under
NCI
POG-9317
POG-9317
Last Modified:
2/1/2001
 
First Published:
7/1/1994
9.
Phase II Study of ProMACE-CytaBOM with Co-Trimoxazole, Filgrastim (G-CSF) and Antiretroviral Therapy in Patients with AIDS-Related Lymphoma (Summary Last Modified 02/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
over 18
NCI
SWOG-9320
NCT00002571, SWOG-9320
Last Modified:
5/9/2006
10.
Phase II Pilot Study of Weekly Escalating Rotational Chemotherapy (VP-16/VCR, DOX/ARA-C, PEG-ASP/TIT, CTX/PRED, and MTX/MP) as Continuation Therapy in Children with Non-T, Non-B-Cell ALL in First Marrow Relapse, with Weekly vs Biweekly PEG-ASP During Induction: SIMAL #7
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
under 22 at initial diagnosis
NCI
POG-9310
POG-9310
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute